Idiopathic Pulmonary Fibrosis Market Expands as Novel Therapies Reshape Treatment

The pipeline is becoming an increasingly important component of the future idiopathic pulmonary fibrosis market. Drug developers are investigating mechanisms associated with fibrosis, inflammation, cellular signaling, and other biological processes involved in disease progression.

DelveInsight highlights emerging candidates such as pamrevlumab, inhaled treprostinil (Tyvaso), C21, PLN-74809, BI 1015550, and BMS-986278. These programs demonstrate the industry's focus on developing differentiated approaches that could complement or improve upon existing antifibrotic treatment.

Regulatory and clinical developments are also contributing to optimism surrounding the pipeline. The approval of JASCAYD (nerandomilast) in the United States in October 2025 represented a notable addition to the IPF treatment landscape. In December 2025, PureTech announced a successful FDA End-of-Phase II meeting for deupirfenidone (LYT-100), with the Phase III SURPASS-IPF study planned for 2026. Such developments highlight the continued push toward therapies with potentially differentiated efficacy and tolerability profiles.

Fibrotic Diseases Treatment Market and Broader Opportunities

The fibrotic diseases treatment market is attracting increasing research interest as scientists investigate biological mechanisms shared across multiple progressive fibrotic disorders. IPF is particularly significant because its irreversible progression and limited therapeutic options create considerable demand for treatments capable of slowing or potentially modifying disease progression.

Advances in molecular profiling, biomarkers, genetics, and disease characterization may improve patient identification and support more personalized treatment strategies. Research presented at the 2024 American Thoracic Society conference explored areas including biomarkers, circulating proteomes, differentiation of fibrotic hypersensitivity pneumonitis from IPF, and methods for predicting disease characteristics and severity.

Idiopathic Interstitial Pneumonias Market and Persistent Unmet Needs

The idiopathic interstitial pneumonias market encompasses a broader group of interstitial lung disorders, with IPF representing one of the most clinically significant progressive fibrotic diseases. Despite improvements in diagnosis and antifibrotic treatment, considerable unmet needs remain.

Delayed diagnosis, progressive loss of lung function, lack of curative treatment, treatment-related tolerability issues, and high mortality continue to present challenges. Future therapies will need to demonstrate meaningful improvements in preserving pulmonary function while potentially offering better safety, quality of life, disease control, and survival outcomes.

Treatments capable of addressing shortcomings associated with current antifibrotic medicines could achieve significant differentiation in both clinical practice and the competitive landscape.

Idiopathic Pulmonary Fibrosis Market Outlook Through 2036

The future of IPF treatment is being shaped by the combination of rising epidemiological demand, therapeutic innovation, and improved recognition of the disease. DelveInsight's forecast evaluates the United States, EU4, the UK, and Japan through 2036, examining patient epidemiology and market performance across therapies and drug classes.